Pacer Advisors Inc. Acquires 1,347,775 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Pacer Advisors Inc. raised its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 51,977.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 1,350,368 shares of the company’s stock after purchasing an additional 1,347,775 shares during the period. Pacer Advisors Inc.’s holdings in Amphastar Pharmaceuticals were worth $50,139,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMPH. KBC Group NV boosted its stake in shares of Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after purchasing an additional 650 shares in the last quarter. Dakota Wealth Management boosted its stake in shares of Amphastar Pharmaceuticals by 31.7% during the fourth quarter. Dakota Wealth Management now owns 5,486 shares of the company’s stock valued at $204,000 after purchasing an additional 1,322 shares in the last quarter. Arkadios Wealth Advisors boosted its stake in shares of Amphastar Pharmaceuticals by 5.2% during the fourth quarter. Arkadios Wealth Advisors now owns 27,964 shares of the company’s stock valued at $1,038,000 after purchasing an additional 1,379 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of Amphastar Pharmaceuticals by 4.8% during the fourth quarter. Nordea Investment Management AB now owns 279,714 shares of the company’s stock valued at $10,386,000 after purchasing an additional 12,851 shares in the last quarter. Finally, World Investment Advisors LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the third quarter valued at about $1,614,000. Institutional investors own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AMPH. StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $60.33.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 6,893 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $48.88, for a total value of $336,929.84. Following the completion of the sale, the executive vice president now directly owns 118,388 shares in the company, valued at approximately $5,786,805.44. The trade was a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Yakob Liawatidewi sold 5,214 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the sale, the executive vice president now owns 74,938 shares of the company’s stock, valued at approximately $3,900,522.90. This represents a 6.51 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,533 shares of company stock worth $1,987,482. 27.10% of the stock is owned by corporate insiders.

Amphastar Pharmaceuticals Trading Up 1.7 %

Shares of AMPH stock opened at $37.11 on Tuesday. The company has a market cap of $1.78 billion, a P/E ratio of 12.37, a PEG ratio of 1.11 and a beta of 0.82. The stock has a 50 day simple moving average of $39.99 and a two-hundred day simple moving average of $44.06. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $34.60 and a fifty-two week high of $56.45.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.